LD-2 disclosure · 3rd Quarter - Report
ASSOCIATION FOR ACCESSIBLE MEDICINES
Client
- Location
- District of Columbia · United States of America
Registrant
- Description
- Association representing the interests of the generic pharmaceutical industry.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
5 issuesTrade (domestic/foreign)
General Trade Issues. Drug Supply Chain.
LobbyistsKARIN HESSLER · KATHERINE RAAB · ILHAAM JAFFER
TargetedSENATE · HOUSE OF REPRESENTATIVES
Pharmacy
Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. S.1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023. H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. Drug Shortages. S.2362 - Drug Shortage Prevention Act. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Drug-Device Combination Products. Third Party Drug Quality Studies. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act.
LobbyistsCRAIG BURTON · KARIN HESSLER · KATHERINE RAAB · PETER KELBEL · ILHAAM JAFFER
TargetedSENATE · HOUSE OF REPRESENTATIVES · Congressional Budget Office (CBO) · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
Medicare Part D Reform. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. H.R.1352/S.3934: Increasing Access to Biosimilars Act of 2023. Medicare Rebate Penalty.
